Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Conversion, Judgment, and Priorities in Postinduction Lung Cancer Surgery.

The Annals of thoracic surgery·2026
Same author

Feasibility and oncologic outcomes of minimally invasive surgery after induction chemoimmunotherapy for non-small cell lung cancer.

JTCVS open·2026
Same author

Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Gastroesophageal Adenocarcinoma.

JCO precision oncology·2026
Same author

Utilization of invasive mediastinal nodal staging and prevalence of occult nodal disease in patients with synchronous primary lung cancers.

Lung cancer (Amsterdam, Netherlands)·2026
Same author

Mentorship, work-life balance, and opportunities amongst cardiothoracic surgery trainees.

JTCVS open·2026
Same author

Social media in surgery: Navigating evidence, sensationalism, and stewardship.

JTCVS open·2026

Related Experiment Video

Updated: Jun 15, 2026

The Application of 1% Methylene Blue Dye As a Single Technique in Breast Cancer Sentinel Node Biopsy
07:51

The Application of 1% Methylene Blue Dye As a Single Technique in Breast Cancer Sentinel Node Biopsy

Published on: June 1, 2019

Therapeutic sentinel lymph node imaging.

Stefan S Kachala1, Elliot L Servais, Bernard J Park

  • 1Division of Thoracic Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.

Seminars in Thoracic and Cardiovascular Surgery
|March 16, 2010
PubMed
Summary
This summary is machine-generated.

New agents for "Therapeutic Sentinel Lymph Node Imaging" can identify and treat cancerous lymph nodes in early-stage non-small cell lung cancer, potentially preventing recurrence.

More Related Videos

Multispectral Real-time Fluorescence Imaging for Intraoperative Detection of the Sentinel Lymph Node in Gynecologic Oncology
06:37

Multispectral Real-time Fluorescence Imaging for Intraoperative Detection of the Sentinel Lymph Node in Gynecologic Oncology

Published on: October 20, 2010

Related Experiment Videos

Last Updated: Jun 15, 2026

The Application of 1% Methylene Blue Dye As a Single Technique in Breast Cancer Sentinel Node Biopsy
07:51

The Application of 1% Methylene Blue Dye As a Single Technique in Breast Cancer Sentinel Node Biopsy

Published on: June 1, 2019

Multispectral Real-time Fluorescence Imaging for Intraoperative Detection of the Sentinel Lymph Node in Gynecologic Oncology
06:37

Multispectral Real-time Fluorescence Imaging for Intraoperative Detection of the Sentinel Lymph Node in Gynecologic Oncology

Published on: October 20, 2010

Area of Science:

  • Oncology
  • Medical Imaging
  • Nanotechnology

Background:

  • Early-stage non-small cell lung cancer (NSCLC) recurrence is often linked to occult micrometastases in sentinel lymph nodes (LNs).
  • Current methods for sentinel lymph node identification in NSCLC lack the sensitivity for detecting minimal metastatic disease.
  • Targeted cytotoxic agents offer potential for improved outcomes in patients with lymph node metastases.

Purpose of the Study:

  • To review novel preclinical agents for "Therapeutic Sentinel Lymph Node Imaging" in non-small cell lung cancer.
  • To explore agents that simultaneously identify and eradicate tumor-bearing lymph nodes.
  • To discuss the clinical translation potential of these innovative agents.

Main Methods:

  • Review of preclinical research on combined imaging and therapeutic agents for sentinel lymph nodes.
  • Analysis of agents targeting molecular detection of micrometastases.
  • Evaluation of cytotoxic agents for eradicating metastatic disease within lymph nodes.

Main Results:

  • Development of novel agents that integrate sentinel lymph node identification with targeted cancer cell eradication.
  • Preclinical evidence suggests these agents can detect and treat tumor-involved lymph nodes.
  • These agents hold promise for reducing recurrence in early-stage NSCLC.

Conclusions:

  • "Therapeutic Sentinel Lymph Node Imaging" represents a promising strategy for managing lymph node metastases in NSCLC.
  • Further development and clinical translation of these agents could significantly improve patient outcomes.
  • This approach may enable precise treatment of micrometastatic disease, preventing cancer recurrence.